$CLS

Chawla Mandeep sold $6.8M of CLS

Chawla Mandeep (Chief Financial Officer) sold 17,000 shares of CELESTICA INC (CLS) at an average of $399.65 ($394.25–$412.99, $6.79M total) across 15 trades on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chawla Mandeep
Published Jun 18, 2026, 12:52 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 18, 2026, 1:05 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CLS
Neutral
medium confidence
Mentioned
$CLS
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLSNeutralLow
01

Why it matters

The disclosure provides a concrete insider activity datapoint (~$6.79M) but does not include new financial results, guidance, or business developments.

02

Market read

A CFO’s 10b5-1 sale of ~$6.79M in CLS is more sentiment/positioning information than a fundamental catalyst.

03

What to watch

Traders may over-weight the sale size; the key nuance is that the plan was pre-arranged, and the filing date is after the trades were already executed (2026-06-15).

Relevance 5/10Novelty 6/10Timing: Filed 2026-06-17 for sales executed 2026-06-15

Background

SEC Form 4 reports an officer (CFO) open-market sale of Celestica shares, executed across 15 trades on 2026-06-15.

Company-level read

Ticker impact

$CLSNeutralMedium confidence
Context

Celestica CFO Chawla Mandeep sold about 17,000 CLS shares in an open-market sale under a 10b5-1 plan, totaling ~$6.79M.

Expected impact

Likely limited/short-lived impact; any reaction should fade unless accompanied by other company-specific catalysts.

Evidence & confidence

The filing is a primary Form 4 disclosure with sizable dollar value, but it explicitly states a pre-arranged 10b5-1 plan, which typically dampens interpretive power.

Market effects

Minimal sector read-through; this is company-specific insider transaction data without operational or guidance content.

No clear regional spillover indicated by the filing details.

Limited global relevance; no deal, regulation, or macro linkage is described.

Counterpoint

Because the trades were executed under a pre-arranged 10b5-1 plan, the sale may reflect liquidity/compensation mechanics rather than bearish fundamentals.

Key entities

  • Celestica Inc

    Issuer of CLS shares; CFO insider sale disclosed on Form 4.

  • Chawla Mandeep

    Chief Financial Officer who sold ~17,000 shares under a 10b5-1 plan.

Related articles

$CLSMedAI 8/10

Celestica Completes Equity Offering

Celestica Inc. (NYSE: CLS, TSX: CLS) said it completed its equity offering of 9,677,419 common shares at $310 per share. Including the underwriters’ option, 11,129,031 shares were sold for about $3.45 billion in gross proceeds. Net proceeds will be used for working capital, capital expenditures, and general corporate purposes.

$CLSHighAI 9/10

Celestica Falls After Pricing $3 Bln Equity Offering

Celestica Inc. (CLS) shares fell nearly 12% after the company priced a $3.0 billion public equity offering. According to the company, it sold 9.68 million common shares at $310 each, raising expected gross proceeds of $3.0 billion, and gave underwriters a 30-day option for up to 1.45 million additional shares. CLS traded around $319.48, down about $43.28.

$CLSHighAI 9/10

Why is Celestica stock sliding today?

Celestica (CLS) shares fell 13.7% after the company priced a $3 billion common stock offering at $310 per share, down from the prior close of $362.76. Celestica plans to sell about 9.68 million treasury shares, with underwriters able to buy 1.45 million more. Management said the raise supports AI compute and networking demand.

$CLSMedAI 8/10

Celestica Announces Pricing of Equity Offering

Celestica Inc. (NYSE: CLS, TSX: CLS) priced an equity offering of 9,677,419 common shares at $310 per share. Gross proceeds are expected at about $3.0 billion before underwriting discounts and expenses. Underwriters have a 30-day option to buy up to 1,451,612 additional shares. Net proceeds will fund working capital and capital expenditures, among other purposes. Closing is expected around Aug. 7, 2026.